ETORICOXIB IN THE TREATMENT OF PATIENTS WITH NEUROLOGICAL AND RHEUMATOLOGIC DISEASES. CONSENSUS OF THE EXPERT COUNCIL
DOI:
https://doi.org/10.31082/1728-452X-2021-225-3-8-19Keywords:
etoricoxib, osteoarthritis, rheumatoid arthritis, coxibs, selective NSAIDsAbstract
In November 2020, an international virtual meeting of the Expert advisory board was held which brought together leading neurology, rheumatology, and therapy experts from Russia, Kazakhstan and Uzbekistan.
The purpose of the meeting. To determine the place of etoricoxib in the treatment of rheumatolo-
gical and neurological diseases accompanied by pain syndrome, to evaluate the efficacy and safety data for the molecule.
Modern rheumatology has made tremendous strides in the treatment of the most common autoimmune diseases, primarily, osteoarthritis and rheumatoid arthritis. The introduction of biologic drugs into clinical practice and the strategy of early aggressive therapy using basic anti-inflammatory drugs have made it possible to achieve sustained clinical remission in a significant proportion of patients. Nevertheless, symptomatic pain relievers retain their most important position in this pathology. However, the use of traditional NSAIDs is associated with adverse events, especially gastrointestinal ones. Coxibs make it possible to solve this medical problem to some extent due to their selectivity. Among coxibs, it is etoricoxib
that has a special position. On the one hand, it is a potent and reliable product for the treatment of pain with a high level of evidence in clinical practice, and on the other hand, it is well tolerated and has a minimal gastropathy risk.
References
Arendt-Nielsen L. Central sensitization in humans: assessment and pharmacology. Handb Exp Pharmacol. 2015;227:79-102. PMID: 25846615. doi: 10.1007/978-3-662-46450-2_5
Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005;39(5):854-62. PMID: 15827069. doi: 10.1345/aph.1E543
Arendt-Nielsen L. Evidence for a central mode of action for etoricoxib (COX-2 Inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug; 157(8):1634-44. doi: 10.1097/j.pain.0000000000000562
Lin H-Y, Cheng T-T, Wang J-H, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010 May;13(2):144–150. PMID: 20536599. doi: 10.1111/j.1756-185X.2010.01468.x
Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability-a randomized, placebo-controlled, 3-month tria. Pain. 2003;4(6):307–15. PMID: 14622687. doi: 10.1016/s1526-5900(03)00633-3
Pallay R, Seger W, Adler J, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257–66. PMID: 15370723. doi: 10.1080/03009740410005728
Zerbini C, Ozturk ZE, Grifka J, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005 Dec;21(12):2037-49. PMID: 16368055. doi: 10.1185/030079905X75069
Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005 May;21(5):715-22. PMID: 15974563. doi: 10.1185/030079905x43686
Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi: 10.1371/journal.pone.0190798.eCollection 2018
Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549):1771-81. PMID: 17113426. doi: 10.1016/S0140-6736(06)69666-9
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-1602. PMID: 27733282. PMCID: PMC5055577. doi: 10.1016/S0140-6736(16)31678-6
O'Dell J.R. Goldman-Cecil Medicine. 25th ed. 2016:1754-1762
American College Of Rheumatology. Updated Guideline for the Management of Rheumatoid Arthritis. Project Plan – October 2018, Available from: https://www.rheumatology.org/Portals/0/Files/Rheumatoid-Arthritis-Guideline-Project-Plan.pdf
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055)2023-2038. doi: https://doi.org/10.1016/S0140-6736(16)30173-8
Walker C. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac [published correction appears in Int J Rheu-matol. 2019 Jun 2;2019:8635073]. Int J Rheumatol. 2018;2018:1302835. Published 2018 Dec 9. doi:10.1155/2018/1302835
Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-265 (In Russ.). doi: http://dx.doi.org/10.14412/1995-4484-2016-247-265
McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi:10.1016/j.joca.2014.01.003. Epub 2014 Jan 24
Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991. PMID: 28087505. doi: 10.1136/annrheumdis-2016-210770
Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;(1):4–23. (In Russ.) doi: http://dx.doi.org/10.14412/1996-7012-2015-1-4-23
Alekseev VV, Barinov AN, Kukushkin ML, et al. Bol: rukovodstvo dlia vrachei i studentov [Pain: a guide for doctors and students] ed. N.N. Yakhno. M.: MedPress. 2009. 302 p.
Zinovievа OE, Rozhkov DO. Multidisciplinary approach to the treatment of chronic nonspecific back pain. Analysis of the clinical case. Reguljarnye vypuski «RMZh» = Regular Issues of the RMJ. 2018;4(II):93-96. (In Russ.). Available from: https://www.rmj.ru/articles/nevrologiya/Mulytidisciplinarnyy_podhod_k_lecheniyu_hronicheskoy_nespecificheskoy_boli_v_spine/#ixzz75eU0LKVL
Karateev AE, Nasonov EL, Ivashkin VT, et al. Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl. 1):
–29 (In Russ.). doi: 10.14412/1995-4484-2018-1-29
Lempp H, Baggott R, Scott DL, et al. The value, impact and role of nurses in rheumatology outpatient care: Critical review of the literature. Musculoskeletal Care. 2020;18:245–255. https://doi.org/10.1002/msc.1467
Referring to other medical specialists / A guide for ensuring good referral outcomes for your patients. The Royal Australian College of General Practitioners 2019
Scaioli G, Schäfer WLA, Boerma WGW, et al. Communication between general practitioners and medical specialists in the referral process: a cross-sectional survey in 34 countries. BMC Fam Pract. 2020;21(1):54. https://doi.org/10.1186/s12875-020-01124-x
Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyper-algesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Aug 2. pii: S1063-4584(17)31091-9. PMID: 28778815. doi: 10.1016/j.joca.2017.07.009
Watson D, Bolognese J, Yu C, et al. Use of gastro-protective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opi. 2004;20(12):1899-1908. PMID: 15701208. doi: 10.1185/030079904X12681
